AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26700485 — intervention group
Group type: EXPERIMENTAL
Intervention: LT4 replacement therapy
Number of subjects: 122
Study 26700485 — intervention group
Group type: COMPARATOR
Intervention: LT4 euthyroid women
Number of subjects: 122
Study 26700706 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course of hypofractionated whole-breast irradiation (WBI) with a boost: 36.63 Gy in 11 fractions of 3.33 Gy over 11 days, followed by a lumpectomy bed boost in 4 fractions of 3.33 Gy
Number of subjects: 83
Study 26701602 — intervention group
Group type: COMPARATOR
Intervention: Recombinant full-length P. vivax ectodomains
Number of subjects: 34
Study 26701835 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized self-report questionnaires for HRQoL and mental health assessment
Number of subjects: 121
Study 26701835 — intervention group
Group type: EXPERIMENTAL
Intervention: Time since child's acute HUS episode
Number of subjects: 121
Study 26701835 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of PTSD
Number of subjects: 121
Study 26701919 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-supported therapy
Number of subjects: 588
Study 26702094 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC01 (single dose) in ART-untreated subjects
Number of subjects: 14
Study 26702094 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC01 (two infusions) in ART-treated subjects
Number of subjects: 14
Study 26702094 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC01 (single dose) in ART-untreated subjects with plasma virus load <1000 copies/ml
Number of subjects: 14
Study 26702094 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC01 (single dose) in ART-untreated subjects with baseline virus loads between 3000 and 30,000 copies
Number of subjects: 14
Study 26702147 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamondback 360® Coronary Orbital Atherectomy System (OAS)
Number of subjects: 0
Study 26702637 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S malaria vaccination at age 6, 10 and 14 weeks with DTP3 coverage
Number of subjects: 42
Study 26702637 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S malaria vaccination at age 6, 7-and-a-half and 9 months with 75% DTP3 coverage
Number of subjects: 42
Study 26702763 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 0
Study 26702763 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 0
Study 26702865 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic Valve Replacement (AVR)
Number of subjects: 97
Study 26702925 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil (600 mg every 12 h)
Number of subjects: 1916
Study 26702925 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (1-2 g every 24 h)
Number of subjects: 1916
Study 26704020 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg per day for 3 days)
Number of subjects: 72
Study 26704020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 26704020 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 72
Study 26704020 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (early initiation before day 6)
Number of subjects: 72
Study 26704020 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (initiation on or after day 6)
Number of subjects: 72
Study 26704148 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir 150 mg once daily + sofosbuvir 400 mg once daily for 12 weeks
Number of subjects: 103
Study 26704148 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir + sofosbuvir
Number of subjects: 103
Study 26704626 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg single dose
Number of subjects: 66
Study 26704626 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg/day for 4 weeks
Number of subjects: 66
Study 26704626 — intervention group
Group type: COMPARATOR
Intervention: Baseline comparison
Number of subjects: 66
Study 26704626 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 66
Study 26704864 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma PAI-1 levels
Number of subjects: 39
Study 26705752 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest and Exercise Adaptation
Number of subjects: 0
Study 26706103 — intervention group
Group type: EXPERIMENTAL
Intervention: (177)Lu-girentuximab, 2405 MBq/m(2) intravenously, with retreatment after 3 months at 75% of the previous dose if no persistent toxicity or progressive disease.
Number of subjects: 14
Study 26706103 — intervention group
Group type: EXPERIMENTAL
Intervention: (177)Lu-girentuximab
Number of subjects: 14
Study 26706294 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-injection intralymphatic immunotherapy
Number of subjects: 0
Study 26706812 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use (SU)
Number of subjects: 52
Study 26706812 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use disorders (SUD)
Number of subjects: 52
Study 26706812 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 52
Study 26706812 — intervention group
Group type: EXPERIMENTAL
Intervention: Health indicators
Number of subjects: 52
Study 26707232 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure to be thin
Number of subjects: 215
Study 26707935 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (Dex) + Venetoclax (ABT-199)
Number of subjects: 0
Study 26707935 — intervention group
Group type: COMPARATOR
Intervention: Venetoclax (ABT-199) alone
Number of subjects: 0
Study 26707935 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (Dex) + Melphalan or Carfilzomib
Number of subjects: 0
Study 26708155 — intervention group
Group type: EXPERIMENTAL
Intervention: Alectinib 600 mg orally twice daily until progression, death, or withdrawal.
Number of subjects: 87
Study 26708155 — intervention group
Group type: EXPERIMENTAL
Intervention: Alectinib
Number of subjects: 87
Study 26708172 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I (hs-cTnI)
Number of subjects: 403
Study 26708172 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-cTnT)
Number of subjects: 403
Study 26708172 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical judgment regarding myocardial ischemia
Number of subjects: 403
Study 26708172 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological stress
Number of subjects: 403
Study 26708830 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine XR monotherapy for up to 16 weeks
Number of subjects: 468
Study 26708836 — intervention group
Group type: EXPERIMENTAL
Intervention: Various behavioral and lifestyle interventions
Number of subjects: 0
Study 26709883 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV immunoglobulin and complete vaccine
Number of subjects: 35
Study 26709883 — intervention group
Group type: COMPARATOR
Intervention: No intervention (negative for HBsAg, HBsAb, and HBcAb)
Number of subjects: 35
Study 26709883 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (lamivudine or tenofovir/emtricitabine) during pregnancy
Number of subjects: 35
Study 26709883 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete vaccine
Number of subjects: 35
Study 26709970 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting Energy Expenditure (REE) in PHP1A participants
Number of subjects: 12
Study 26709970 — intervention group
Group type: COMPARATOR
Intervention: Control group of obese participants
Number of subjects: 12
Study 26710961 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (one or two doses)
Number of subjects: 33
Study 26710961 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (second double dose)
Number of subjects: 33
Study 26711162 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 732
Study 26711162 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Turkey
Number of subjects: 732
Study 26711162 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 732
Study 26711162 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress as a precipitator of relapse
Number of subjects: 732
Study 26711162 — intervention group
Group type: EXPERIMENTAL
Intervention: Health as motivation for quit attempt
Number of subjects: 732
Study 26711162 — intervention group
Group type: EXPERIMENTAL
Intervention: Family/Social pressures as motivation
Number of subjects: 732
Study 26711162 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost as motivation
Number of subjects: 732
Study 26711162 — intervention group
Group type: EXPERIMENTAL
Intervention: Cravings as pre-cessation concern
Number of subjects: 732
Study 26711162 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress as pre-cessation concern
Number of subjects: 732
Study 26711162 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of failure as pre-cessation concern
Number of subjects: 732
Study 26711162 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns about cravings in participants with psychotic and anxiety disorders
Number of subjects: 732
Study 26711162 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns about stress and fear of failure in participants with anxiety
Number of subjects: 732
Study 26711546 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (CR) prescription at discharge
Number of subjects: 2894
Study 26711747 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-493 (doses ranging from 100 mg to 700 mg)
Number of subjects: 40
Study 26711747 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-530 (doses of ≥ 40 mg)
Number of subjects: 40
Study 26711747 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-493
Number of subjects: 40
Study 26711747 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-530
Number of subjects: 40
Study 26711747 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-493 and ABT-530
Number of subjects: 40
Study 26711756 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g Azithromycin (AZI) given during labor
Number of subjects: 20
Study 26711756 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin in breast milk
Number of subjects: 20
Study 26711775 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g doripenem every 8 h
Number of subjects: 13
Study 26711777 — intervention group
Group type: EXPERIMENTAL
Intervention: AFN-1252, 200 mg given by mouth twice daily
Number of subjects: 103
Study 26711792 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive inguinal lymphadenectomy (MILND) after a structured training program
Number of subjects: 88
Study 26711792 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive inguinal lymphadenectomy (MILND)
Number of subjects: 88
Study 26712084 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab 2 mg/kg
Number of subjects: 1034
Study 26712084 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab 10 mg/kg
Number of subjects: 1034
Study 26712084 — intervention group
Group type: COMPARATOR
Intervention: docetaxel
Number of subjects: 1034
Study 26712084 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab 2 mg/kg (in patients with at least 50% PD-L1 expression)
Number of subjects: 1034
Study 26712084 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab 10 mg/kg (in patients with at least 50% PD-L1 expression)
Number of subjects: 1034
Study 26712084 — intervention group
Group type: COMPARATOR
Intervention: docetaxel (in patients with at least 50% PD-L1 expression)
Number of subjects: 1034
Study 26712084 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Number of subjects: 1034
Study 26712110 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US)
Number of subjects: 2809
Study 26712327 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of therapies
Number of subjects: 0
Study 26712327 — intervention group
Group type: COMPARATOR
Intervention: Expensive biologic drug
Number of subjects: 0
Study 26712453 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline body mass index (BMI)
Number of subjects: 94
Study 26712453 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density lipoprotein (HDL) cholesterol
Number of subjects: 94
Study 26712453 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of diabetes (FHD)
Number of subjects: 94
Study 26712453 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline risk markers
Number of subjects: 94
Study 26714500 — intervention group
Group type: EXPERIMENTAL
Intervention: High physical activity (cpm > 31)
Number of subjects: 200
Study 26714500 — intervention group
Group type: EXPERIMENTAL
Intervention: Low physical activity (cpm ≤ 31)
Number of subjects: 200
Study 26714500 — intervention group
Group type: EXPERIMENTAL
Intervention: High physical activity (cpm > 31) in patients with diabetes
Number of subjects: 200
Study 26714500 — intervention group
Group type: EXPERIMENTAL
Intervention: Low physical activity (cpm ≤ 31) in patients with diabetes
Number of subjects: 200
Study 26714500 — intervention group
Group type: EXPERIMENTAL
Intervention: High physical activity (cpm > 31) in controls
Number of subjects: 200
Study 26714500 — intervention group
Group type: EXPERIMENTAL
Intervention: Low physical activity (cpm ≤ 31) in controls
Number of subjects: 200
Study 26714738 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFα inhibitors
Number of subjects: 0
Study 26714738 — intervention group
Group type: COMPARATOR
Intervention: TNFα stimulation in T cells from healthy controls (HC)
Number of subjects: 0
Study 26714738 — intervention group
Group type: EXPERIMENTAL
Intervention: Bryostatin-1 experiments
Number of subjects: 0
Study 26714738 — intervention group
Group type: COMPARATOR
Intervention: TNFα
Number of subjects: 0
Study 26714769 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary care for 1 year
Number of subjects: 40
Study 26714807 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway Medix Closed Suction System™, cleaning group
Number of subjects: 40
Study 26714807 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no ETT cleaning, standard closed suction), control group
Number of subjects: 40
Study 26714807 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 26715442 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy-related toxicities (severe neutropenia grades ≥3)
Number of subjects: 6248
Study 26715442 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy-related toxicities (fatigue grades ≥3)
Number of subjects: 6248
Study 26715442 — intervention group
Group type: EXPERIMENTAL
Intervention: NEAT/BR9601 sub-group analysis (fatigue grades ≥3)
Number of subjects: 6248
Study 26715447 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month guided weight loss intervention (twice weekly classes and text messaging)
Number of subjects: 240
Study 26715447 — intervention group
Group type: COMPARATOR
Intervention: Self-guided weight loss intervention (based on the same materials as the guided program)
Number of subjects: 240
Study 26715570 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac MRI (CMR) based feature tracking (FT) measuring longitudinal (LS), circumferential (CS), and radial global strain (RS)
Number of subjects: 372
Study 26715573 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg orally daily, gemcitabine 1000 mg/m2 intravenously on days 1, 8, 15, and capecitabine 850 mg/m2 orally twice daily on days 1-21.
Number of subjects: 23
Study 26715573 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib 200 mg orally daily (during dose escalation phase).
Number of subjects: 23
Study 26715573 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of gemcitabine, capecitabine, and vandetanib.
Number of subjects: 23
Study 26716164 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient non-cardiac surgery
Number of subjects: 3927
Study 26716164 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgent or emergency surgical procedures
Number of subjects: 3927
Study 26717401 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep-disordered breathing (SDB) assessment via apnea/hypopnea index (AHI) > 5/h
Number of subjects: 62
Study 26717401 — intervention group
Group type: EXPERIMENTAL
Intervention: Epworth Sleepiness Scale (ESS) assessment
Number of subjects: 62
Study 26717401 — intervention group
Group type: EXPERIMENTAL
Intervention: Mainz Severity Score Index (MSSI) assessment
Number of subjects: 62
Study 26717401 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable analysis of predictors of SDB
Number of subjects: 62
Study 26717401 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of ESS with depression
Number of subjects: 62
Study 26717526 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram at a dose of 20-60 mg/d for 12 weeks
Number of subjects: 3984
Study 26717906 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based e-workbook for child mental health treatment
Number of subjects: 20
Study 26718090 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative oxygen therapy (target SpO2 88-92% using the lowest FiO2)
Number of subjects: 100
Study 26718090 — intervention group
Group type: COMPARATOR
Intervention: Conventional oxygen therapy
Number of subjects: 100
Study 26718413 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding (BF)
Number of subjects: 932
Study 26718413 — intervention group
Group type: COMPARATOR
Intervention: Formula Feeding (FF)
Number of subjects: 932
Study 26718413 — intervention group
Group type: COMPARATOR
Intervention: Mixed Feeding (MF)
Number of subjects: 932
Study 26718501 — intervention group
Group type: EXPERIMENTAL
Intervention: SLC19A3 SNPs
Number of subjects: 134
Study 26718501 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis including WESDR cohort
Number of subjects: 134
Study 26718690 — intervention group
Group type: EXPERIMENTAL
Intervention: Seroprevalence of pertussis antibodies
Number of subjects: 0
Study 26718690 — intervention group
Group type: EXPERIMENTAL
Intervention: Current or recent infection
Number of subjects: 0
Study 26718690 — intervention group
Group type: COMPARATOR
Intervention: Pertussis prevalence by demographics
Number of subjects: 0
Study 26718759 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol plasma clearance
Number of subjects: 43
Study 26718759 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineralocorticoid receptor antagonists
Number of subjects: 43
Study 26718759 — intervention group
Group type: COMPARATOR
Intervention: Creatinine-based renal function estimating equations
Number of subjects: 43
Study 26719427 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline levels of IL6
Number of subjects: 73
Study 26719427 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline levels of IL10
Number of subjects: 73
Study 26719427 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of MCP-1
Number of subjects: 73
Study 26719427 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater proportion of CD45RO(+) T cells (CD4)
Number of subjects: 73
Study 26719427 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater proportion of CD45RO(+) T cells (CD8)
Number of subjects: 73
Study 26719427 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater expression of CTLA-4 on CD8(+) T cells
Number of subjects: 73
Study 26719427 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of TIM3 on CD4(+) T cells
Number of subjects: 73
Study 26719433 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood citrulline
Number of subjects: 33
Study 26719433 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal fatty acid binding protein
Number of subjects: 33
Study 26719803 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum Arabic (GA) 30 g/day for 12 weeks
Number of subjects: 47
Study 26719807 — intervention group
Group type: EXPERIMENTAL
Intervention: FD-OCT
Number of subjects: 12
Study 26719807 — intervention group
Group type: COMPARATOR
Intervention: IVUS
Number of subjects: 12
Study 26719807 — intervention group
Group type: EXPERIMENTAL
Intervention: FD-OCT postdilation
Number of subjects: 12
Study 26719807 — intervention group
Group type: COMPARATOR
Intervention: IVUS postdilation
Number of subjects: 12
Study 26719818 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker combinations (urinary neutrophil gelatinase lipocalin (NGAL), kidney injury molecule-1 (KIM-1), liver-type fatty acid binding protein (l-FABP), interleukin-18 (IL-18))
Number of subjects: 5500
Study 26719818 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in serum creatinine and urine output, cumulative fluid overload (%), serum creatinine corrected for fluid balance, and KDIGO AKI stage
Number of subjects: 5500
Study 26719818 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker combinations
Number of subjects: 5500
Study 26720423 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg/d orally until disease progression, with continuation at discretion after progression.
Number of subjects: 208
Study 26720423 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib continued after progression in 93 patients.
Number of subjects: 208
Study 26720423 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib in patients with exon 19 deletions or L585R mutations.
Number of subjects: 208
Study 26720423 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib therapy overall.
Number of subjects: 208
Study 26720423 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib therapy in safety population (n = 207).
Number of subjects: 208
Study 26720423 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-based assessment of EGFR mutations.
Number of subjects: 208
Study 26720426 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper endoscopy with multistaged esophageal biopsies under general anesthesia
Number of subjects: 120
Study 26720750 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinus node dysfunction (SND)
Number of subjects: 9631
Study 26720750 — intervention group
Group type: COMPARATOR
Intervention: Patients without sinus node dysfunction (Control)
Number of subjects: 9631
Study 26721814 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 26721819 — intervention group
Group type: EXPERIMENTAL
Intervention: Palatinose intake
Number of subjects: 0
Study 26721819 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose intake
Number of subjects: 0
Study 26721819 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0